These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 20726495)
1. [The workings of the Drug Bulletin]. Bijl D; Vissink A Ned Tijdschr Tandheelkd; 2010; 117(7-8):372-6. PubMed ID: 20726495 [TBL] [Abstract][Full Text] [Related]
2. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
3. [Drug advertising as communication between the pharmaceutical industry and the physician: advertisements for psychotropic drugs in the Dutch medical journal, Nederlands Tijdschrift voor Geneeskunde, 1900-1940]. van der Hoogte AR; Pieters T Studium (Rotterdam); 2010; 3(4):139-54. PubMed ID: 22586821 [TBL] [Abstract][Full Text] [Related]
4. Pharmacist-physician co-operation at a regional level. Blom AT; Paes AH; Bakker A; Koopman CJ; van der Meer C Pharm World Sci; 1994 Feb; 16(1):13-7. PubMed ID: 8156043 [TBL] [Abstract][Full Text] [Related]
5. Claims in advertisements for antihypertensive drugs in a Dutch medical journal. Greving JP; Denig P; de Zeeuw D; Haaijer-Ruskamp FM J Hypertens; 2007 Mar; 25(3):713-22. PubMed ID: 17278989 [TBL] [Abstract][Full Text] [Related]
6. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica. Dobrić I Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489 [TBL] [Abstract][Full Text] [Related]
7. [Procedures and methods of benefit assessments for medicines in Germany]. Bekkering GE; Kleijnen J Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813 [TBL] [Abstract][Full Text] [Related]
8. [Drug-promoting advertisements in the Dutch Journal of Medicine and Pharmaceutical Weekly: not always evidence based]. van Eeden AE; Roach RE; Halbesma N; Dekker FW Ned Tijdschr Geneeskd; 2012; 156(1):A3999. PubMed ID: 22217308 [TBL] [Abstract][Full Text] [Related]
9. [New drugs available more quickly for the right patient]. Kievit W; Berden FA; Drenth JP Ned Tijdschr Geneeskd; 2016; 160():D735. PubMed ID: 27734779 [TBL] [Abstract][Full Text] [Related]
10. [Threshold value for reimbursement of costs of new drugs: cost-effectiveness research and modelling are essential links]. Frederix GW; Hövels AM; Severens JL; Raaijmakers JA; Schellens JH Ned Tijdschr Geneeskd; 2015; 159():A7728. PubMed ID: 26083839 [TBL] [Abstract][Full Text] [Related]
11. Drug and Therapeutics Bulletin at 40. Drug Ther Bull; 2002 Apr; 40(4):25-6. PubMed ID: 11995263 [TBL] [Abstract][Full Text] [Related]
13. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149 [TBL] [Abstract][Full Text] [Related]
14. Stimulating adverse drug reaction reporting: effect of a drug safety bulletin and of including yellow cards in prescription pads. Castel JM; Figueras A; Pedrós C; Laporte JR; Capellà D Drug Saf; 2003; 26(14):1049-55. PubMed ID: 14583065 [TBL] [Abstract][Full Text] [Related]
15. [Cost-effectiveness of new drugs impacts reimbursement decision making but room for improvement]. Hoomans T; van der Roer N; Severens JL; Delwel GO Ned Tijdschr Geneeskd; 2010; 154():A958. PubMed ID: 20699045 [TBL] [Abstract][Full Text] [Related]
16. [New medicines at an acceptable cost?]. Bijl D Ned Tijdschr Geneeskd; 2015; 160():D170. PubMed ID: 26980467 [TBL] [Abstract][Full Text] [Related]
17. Progress and dilemma of contemporary clinical pharmacology. Herman ZS Int J Clin Pharmacol Ther; 2005 Jan; 43(1):43-50. PubMed ID: 15704614 [TBL] [Abstract][Full Text] [Related]
18. [Dutch authors in international medical journals are also authors of publications in the Nederlands Tijdschrift voor Geneeskunde (Dutch Journal of Medicine)]. Veenemans J; Hoogeveen J; Overbeke AJ Ned Tijdschr Geneeskd; 2005 Nov; 149(46):2573-6. PubMed ID: 16320669 [TBL] [Abstract][Full Text] [Related]
19. Developing a paediatric drug formulary for the Netherlands. van der Zanden TM; de Wildt SN; Liem Y; Offringa M; de Hoog M; Arch Dis Child; 2017 Apr; 102(4):357-361. PubMed ID: 27799154 [TBL] [Abstract][Full Text] [Related]
20. Adherence of pharmacoeconomic studies to national guidelines in the Netherlands. Atthobari J; Bos JM; Boersma C; Brouwers JR; de Jong-van den Berg LT; Postma MJ Pharm World Sci; 2005 Oct; 27(5):364-70. PubMed ID: 16341742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]